

### **Amendments to the Claims**

No amendments to the claims have been made.

### **Listing of the Claims**

Claims 1, 2 and 5-20 are pending in this application.

1. (Previously Presented) A dosage form useful in ophthalmic treatment having a predetermined liquid volume of from about 3 to 20  $\mu\text{l}$ , the dosage form being a jet or stream of droplets of treatment fluid, each droplet having an ophthalmologically active compound in suspension or solution and wherein the jet or each droplet of a size sufficient to sustain momentum along a substantially horizontal path 5 cms in length from a discharge velocity of up to 25 m/sec from the delivery device, wherein substantially the entire dosage form is delivered to the target site and where the jet or stream of droplets is a moving volume of liquid droplets, where the volume has a length and diameter that remain substantially unchanged between exiting the delivery device and contacting the target site.
2. (Original) A dosage form according to claim 1 wherein the jet or each droplet has the active compound in aqueous suspension or solution.
5. (Previously Presented) A dosage form according to claim 1 wherein the jet or each droplet has a diameter in the range 100 to 800  $\mu\text{m}$ .
6. (Original) A dosage form according to claim 5 wherein the jet or each droplet has a diameter in the range 200 to 400  $\mu\text{m}$ .
7. (Previously Presented) A dosage form according to claim 1 in which the total volume of treatment fluid does not exceed 10  $\mu\text{l}$ .
8. (Original) A dosage form according to claim 7 in which the total volume of treatment fluid is in the range 3 to 8  $\mu\text{l}$ .
9. (Previously Presented) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to claim 1.
10. (Original) A method according to claim 9 wherein the eye is a human eye.
11. (Previously Presented) A method according to claim 9 wherein the dosage form is directed at a particular site in the eye.

12. (Previously Presented) A method of increasing the ocular bioavailability of ophthalmologically active compound, wherein the compound is provided in suspension or solution in a body of ophthalmic treatment liquid in a dosage form comprising the liquid as a jet and/or stream of droplets, the jet and/or each droplet being of a size sufficient to sustain momentum in transmission from a delivery device to a target site within an eye, the jet and/or droplets having a mean diameter in the range 20  $\mu\text{m}$  to 1000  $\mu\text{m}$ .
13. (Previously Presented) A method according to claim 12 wherein the mean diameter of the jet and/or droplets is in the range 100  $\mu\text{m}$  to 800  $\mu\text{m}$ .
14. (Previously Presented) A method according to claim 12 wherein the total volume of treatment liquid in the dosage form does not exceed 10  $\mu\text{l}$ .
15. (Original) A method according to claim 14 wherein the total volume of treatment liquid in the dosage form is in the range 3  $\mu\text{l}$  to 8  $\mu\text{l}$ .
16. (Previously Presented) A dosage form according to claim 3 wherein the jet or each droplet has a diameter in the range 100 to 800  $\mu\text{m}$ .
17. (Previously Presented) A dosage form according to claim 3 wherein the jet or each droplet has a diameter in the range 200 to 400  $\mu\text{m}$ .
18. (Previously Presented) A dosage form according to claim 17 in which the total volume of treatment fluid does not exceed 10  $\mu\text{l}$ .
19. (Previously Presented) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to claim 8.
20. (Previously Presented) A method according to claim 12 wherein the mean diameter of the jet and/or droplets is in the range of 200  $\mu\text{m}$  to 400  $\mu\text{m}$ .